Connect with us

Healthcare

Cuomo Receives Award For ‘Inspired Leadership’ During Covid-19: Critics Question His Achievements

Published

on

Screenshot 2020 03 10 14.31.09

New York Governor Andrew Cuomo received the “Edward M. Kennedy Institute Award for Inspired Leadership” during the Covid-19 pandemic. Massachusetts Gov. Charlie Baker will also receive the same award.

“I am honored to receive the 2020 Edward M. Kennedy Institute Award for Inspired Leadership,” tweeted Gov. Cuomo. “I learned about humanity, leadership and putting people first from the great Senator Ted Kennedy.” Guomo congratulated his fellow recipient Gov. Charlie Baker for the award.

Cuomo also received an Emmy Award for the viral press conferences he held in the early stages of the coronavirus pandemic.

But not everyone is happy with how the NY Governor has handled the virus in the state. As of December 7th, there have been 7,147 reported Covid-19 deaths in Nursing and Adult Care facilities throughout the state. Many of these critics associate Cuomo’s directive to take in Covid-19 patients back in March with thousands of deaths in nursing homes.

“Leadership is about good and sound judgment. Gov. Cuomo exercised misguided leadership. He’s responsible for this nursing home problem, and the deaths are on his hands,” Michael Caputo, assistant secretary for public affairs at the US Department of Health and Human Services, told The New York Post back in May.

Between March 25 and May 8, approximately 6,326 COVID-positive patients were admitted to nursing homes, according to a state health department report.

Despite all the critics none of these claims have ever been proven.

Click image to read in full Gov. Cuomo advisory on admissions to nursing homes:

Screen Shot 2020 12 13 at 10.06.56 AM
Continue Reading

Healthcare

Supreme Court rules anti-abortion doctors lack standing to sue FDA

Published

on

Supreme Court

In a unanimous decision on Thursday, the Supreme Court ruled that the anti-abortion doctors who challenged the Food and Drug Administration’s (FDA) approval of the abortion pill mifepristone lack the standing to sue the federal agency. This ruling preserves the FDA’s existing approval of the drug.

The opinion, authored by Justice Brett Kavanaugh, emphasized that the plaintiffs presented “several complicated causation theories to connect FDA’s actions to the plaintiffs’ alleged injuries in fact.” However, none of these theories were sufficient to establish Article III standing, which requires a personal stake in the dispute.

National Review reports the lawsuit was filed in November 2022 by the Alliance Defending Freedom (ADF) on behalf of the Alliance for Hippocratic Medicine and four pro-life doctors. The plaintiffs claimed that the FDA had no authority to approve the two-pill chemical-abortion regimen under Subpart H, a federal code section allowing expedited approval for drugs treating “serious or life-threatening illnesses.” They argued that pregnancy is not an illness but a normal physiological state.

The plaintiffs also challenged the FDA’s 2016 and 2021 decisions to relax restrictions on mifepristone, such as increasing the gestational age for its use, reducing required office visits, allowing non-doctors to prescribe the pills, and permitting mail delivery during the COVID-19 pandemic.

Abortion opponents expressed disappointment with the decision. Erin Hawley, a lawyer with ADF, criticized the FDA for allegedly endangering women by allowing the use of mifepristone without in-person medical supervision. Ingrid Skop from the Charlotte Lozier Institute and Katie Daniel from Susan B. Anthony Pro-Life America echoed similar sentiments, stressing their concerns about the safety of mail-order abortion drugs.

President Joe Biden, however, applauded the decision, highlighting the ongoing risks to women’s rights to necessary medical treatment in many states.

Justice Kavanaugh’s opinion stated that the plaintiffs did not demonstrate a direct injury that would force them to participate in abortion procedures against their conscience. He added that concerns about the potential for increased emergency room visits did not justify legal standing.

Kavanaugh noted that doctors and citizens opposed to FDA regulations should seek changes through legislative and executive branches rather than the courts. This decision aligns with a previous lower court ruling that found the legal challenge was filed too late, beyond the statute of limitations.

Earlier this year, U.S. District Judge Matthew Kacsmaryk in Texas ruled in favor of the plaintiffs, suspending the FDA’s approval of mifepristone. This decision was subsequently overturned by the Fifth Circuit Court of Appeals, which restored access to the drug. The Supreme Court’s stay ensured that the drug remained available while legal proceedings continued.

Democratic lawmakers welcomed the Supreme Court’s ruling. Congresswoman Ayanna Pressley described it as a “major relief & victory for anyone who has ever or will ever need essential medication abortion care.” Senator Elizabeth Warren criticized the challenge as baseless and underscored the safety and effectiveness of chemical-abortion pills. She warned of ongoing efforts by Republicans to impose a nationwide abortion ban and called for continued protection of reproductive freedom.

 

Continue Reading

Trending